Is JNJ in trouble?
Johnson & Johnson is mainly owned by institutional investors, with over 70% of shares held. The 10 largest shareholder of Johnson & Johnson in December 2023 were: The Vanguard Group (9.52%) BlackRock (7.73%)Johnson & Johnson Founding

In 1886, the pharmacist Robert Wood Johnson formed a new company with his brothers James Wood Johnson and Edward Mead Johnson. The brothers founded their company based on Joseph Lister's then-recent research into the nature of airborne germs and infectious disease.It includes prescription and over-the-counter drugs, orthopedic implants, surgical products and household products. The most popular consumer brands include Band-Aids, Tylenol and Johnson's Baby Powder. Still, the bulk of J&J's revenue comes from prescription drugs and medical devices.

Does J&J own Pfizer : Johnson & Johnson Buys Pfizer Unit for $16.6 Billion – The New York Times.

Who is the largest shareholder of JNJ

The company's largest shareholder is The Vanguard Group, Inc., with ownership of 9.5%. BlackRock, Inc. is the second largest shareholder owning 7.7% of common stock, and State Street Global Advisors, Inc. holds about 5.5% of the company stock.

Does Johnson & Johnson own Pfizer : Johnson & Johnson acquired Pfizer's consumer healthcare business, expanding the company's capacity to meet rising global needs.

The company's largest shareholder is The Vanguard Group, Inc., with ownership of 9.5%. BlackRock, Inc. is the second largest shareholder owning 7.7% of common stock, and State Street Global Advisors, Inc. holds about 5.5% of the company stock.

Johnson & Johnson's stock was on pace for its lowest close since late 2020 on Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations.

Is JNJ a good stock to buy

In the last year, 23 stock analysts published opinions about JNJ-N. 15 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock.In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.The main competitors of Johnson & Johnson include Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Eli Lilly and Company (LLY), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX).

The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.

Is JNJ going to split up : NEW BRUNSWICK, N.J., July 24, 2023 — Johnson & Johnson (NYSE: JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc.

Who owns the most JNJ stock : According to the latest TipRanks data, approximately 58.62% of Johnson & Johnson (JNJ) stock is held by retail investors. Vanguard owns the most shares of Johnson & Johnson (JNJ).

Is JNJ a safe investment

I would argue Johnson & Johnson isn't worth the risk. And given the uncertainty it faces and its low growth rate, it's too expensive, even at what might seem to be a modest 22 times earnings. Instead of investing in Johnson & Johnson, I suggest you consider a better and safer investment in AstraZeneca (NASDAQ: AZN).

Johnson & Johnson isn't the safe stock it used to be

But that's no longer the case. Until there is a resolution to the talc-related issues, the stock is simply too big of a risk these days. The legal bills pose a threat to the company's dividend and its long-term growth objectives.Guidance narrowed

Johnson & Johnson narrowed its full-year guidance slightly; the lowered top end of the range likely also contributed to the stock's sell-off. The company is now forecasting total sales of $88 billion to $88.4 billion; previously, it was guiding for $87.8 billion to $88.6 billion.

Why was Johnson and Johnson banned : Johnson & Johnson's Baby Products and Bans

However, Johnson & Johnson's baby products containing talc were discovered to contain asbestos, which is a cancer-causing agent. This discovery led to the European Union banning talc-containing products, as the mineral talc can actually contain the mineral asbestos within it.

Is Johnson & Johnson Stock a Buy Now? | Johnson and Johnson (JNJ) Stock Analysis! |

Buy the Dip? Why JNJ Stock Could Be a Solid Investment Now